VIA Pharmaceuticals VIAP · USD

Its shares trade under the ticker VIAP. It has been listed since 18 April 2000.

VIA Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of compounds for the treatment of cardiovascular diseases. The company is headquartered in San Francisco, California. The company went IPO on 2000-04-18. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Douglass GivenChairman of the Board, since 2007
• Dr. Lawrence CohenPresident, Chief Executive Officer, Director, since 2007
• Ms. Karen WrightPrincipal Financial Officer, Vice President, Controller$7,350
• Dr. Rebecca TaubSenior Vice President - Research and Development$301,080
• Mr. Mark BagnallIndependent Director
• Dr. Frederick CravesIndependent Director
• Mr. David HowardIndependent Director
• Mr. John LarsonIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.